RARA Recombinant Monoclonal Antibody

說明書

中文名稱：

RARA重組抗體
貨號：

CSB-RA019338A0HU
規(guī)格：

￥1320
圖片：
IHC image of CSB-RA019338A0HU diluted at 1:155 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情

產(chǎn)品詳情

產(chǎn)品描述：

CSB-RA019338A0HU RARA重組單克隆抗體是針對維甲酸受體α（RARA）研發(fā)的高特異性檢測工具，適用于ELISA和免疫組化（IHC）實驗，其中IHC實驗推薦使用1:50-1:200的稀釋范圍。該抗體靶向的RARA蛋白屬于核激素受體家族，在細胞分化、凋亡調(diào)控及胚胎發(fā)育中發(fā)揮重要作用，其異常表達與多種腫瘤的發(fā)生發(fā)展密切相關(guān)。經(jīng)多種實驗驗證，本產(chǎn)品能特異性識別天然及重組RARA蛋白，在組織切片中展現(xiàn)出清晰的亞細胞定位信號，背景干擾低，重復(fù)性優(yōu)異。適用于研究RARA在腫瘤發(fā)生、細胞分化異常等病理過程中的作用機制，也可用于藥物靶點篩選及信號通路研究等基礎(chǔ)科研領(lǐng)域。通過嚴格的質(zhì)量控制體系，確保不同批次間性能穩(wěn)定，為研究者提供精準可靠的實驗結(jié)果。
Uniprot No.：

P10276
基因名：

RARA
別名：

NR1B1 antibody; Nuclear mitotic apparatus protein retinoic acid receptor alpha fusion protein antibody; Nuclear receptor subfamily 1 group B member 1 antibody; Nucleophosmin retinoic acid receptor alpha fusion protein NPM RAR long form antibody; RAR alpha antibody; RAR antibody; RAR-alpha antibody; rara antibody; RARA_HUMAN antibody; RARalpha antibody; RARalpha1 antibody; Retinoic acid nuclear receptor alpha variant 1 antibody; Retinoic acid nuclear receptor alpha variant 2 antibody; Retinoic acid receptor alpha antibody; Retinoic acid receptor alpha polypeptide antibody
反應(yīng)種屬：

Human
免疫原：

A synthesized peptide derived from human RARA
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號：

4A10
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

功能：

Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone deacetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. Formation of a complex with histone deacetylases might lead to inhibition of RARE DNA element binding and to transcriptional repression. Transcriptional activation and RARE DNA element binding might be supported by the transcription factor KLF2. RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis. Has a role in the survival of early spermatocytes at the beginning prophase of meiosis. In Sertoli cells, may promote the survival and development of early meiotic prophase spermatocytes. In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function. Together with RXRA, positively regulates microRNA-10a expression, thereby inhibiting the GATA6/VCAM1 signaling response to pulsatile shear stress in vascular endothelial cells. In association with HDAC3, HDAC5 and HDAC7 corepressors, plays a role in the repression of microRNA-10a and thereby promotes the inflammatory response.
基因功能參考文獻：
1. Semiquantitative and quantitative analyses of the markers RARA and CRABP2 indicate their potential as biomarkers for tumor progression and their participation in nephroblastoma tumorigenesis PMID: 29378601
2. The level of RARalpha gene expression as a potential prognostic factor in the pathogenesis of multiple myeloma. PMID: 29119395
3. The data demonstrate that RARalpha drives integrin beta7-dependent adhesion and CCR9-mediated chemotaxis in CTCL cells. PMID: 28370539
4. Silencing of PML-RAR and RARalpha2 results in similar increases in the constitutive expression of several granulocytic differentiation markers. PMID: 27419624
5. RARA drives cyclin-dependent kinase expression, G1-S transition, and cell growth in T-cell lymphoma. PMID: 28412739
6. Demonstrate that RARalpha was frequently elevated in gastric carcinoma and exerted oncogenic properties via positive feedback loop of IL-1beta/Akt/RARalpha/Akt signaling. PMID: 28035062
7. Our findings unveil a novel essential oncogenic activity of PML/RARA in Acute promyelocitic leukemia PMID: 27626703
8. Findings reveal a previously unrecognized role of c-Myc as a potential ceRNA for PML/RARalpha in acute promyelocytic leukemia. PMID: 27486764
9. RARalpha regulates Arp2/3-mediated actin cytoskeletal dynamics through a non-genomic signaling pathway PMID: 26848712
10. It has been shown that the AP-1 family member JunB and retinoic acid receptor alpha (RARa) mediate catalase transcriptional activation and repression, respectively, by controlling chromatin remodeling through a histone deacetylases-dependent mechanism. PMID: 27591797
11. Work identifies the TP53 tumor suppressor as a novel target through which NPM1-RARA impacts leukemogenesis. PMID: 26754533
12. Dual small interfering RNA (siRNA) silencing of RARalpha and RARgamma reversed RA blockade of P4-induced CK5. Using promoter deletion analysis, we identified a region 1.1 kb upstream of the CK5 transcriptional start site that is necessary for P4 activation and contains a putative progesterone response element (PRE PMID: 28692043
13. High RARA expression is associated with acute myeloid leukemia. PMID: 28416638
14. Data suggest that the binding of Z-10 to RXRalpha inhibited the interaction of RXRalpha with PML-RARalpha, leading to Z-10's selective induction of PML-RARalpha degradation. PMID: 28129653
15. PML-RARa bcr1 fusion is not responsible for colorectal tumor development. PMID: 22167334
16. overexpression of NLS-RARalpha promoted the proliferation of APL cells and inhibited their differentiation via the PI3K/AKT signaling pathway. PMID: 27840989
17. r study demonstrated that ATRA cound promote differentiation while inhibit proliferation of acute promyelocytic leukemia NB4 cells via activating p38a protein after recruiting p38a-combinded NLS-RARa, while NLS-RARa could inhibit the effects of ATRA in the process. PMID: 27499693
18. Low expression of RARalpha was independently associated with worse progression-free survival following platinum-based chemotherapy of advanced Non-small cell lung cancer. PMID: 27306217
19. The classical counterpart of RARalpha, retinoid X receptor alpha (RXRalpha), was down-regulated in both cytoplasm and nucleus of A549 cells upon atRA addition. PMID: 26818829
20. RAI1 polymorphisms rs4925102 and rs9907986 are predicted to disrupt the binding of retinoic acid RXR-RAR receptors and the transcription factor DEAF1, respectively, in Smith-Magenis and Potocki-Lupski syndromes patients. PMID: 26743651
21. Data suggest that hematopoietically expressed homeobox protein (HHEX) downmodulation by promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein (PML-RARalpha) is a key event during acute promyelocytic leukemia (APL) pathogenesis. PMID: 27052408
22. ATRA dramatically down regulated RARalpha protein levels and led to more DNA damage and ultimately resulted in the synergism of these two agents PMID: 26728137
23. NPM-RAR binding to TRADD selectively inhibits caspase activation, while allowing activation of NFkappaB and JNK PMID: 25791120
24. Suggest a novel role of PCGF2 in arsenic trioxide-mediated degradation of PML-RARA that PCGF2 might act as a negative regulator of UBE2I via direct interaction. PMID: 27030546
25. down-regulation of the level of RAR alpha leads to increased expression of VDR in acute myeloid leukemia. PMID: 26969398
26. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARalpha protein degradation in acute promyelocytic leukemia. PMID: 26213848
27. Novel insight into the functional difference of acquired mutations of PML-RARA both in vitro and in the clinical setting. PMID: 26537301
28. our findings challenge the predominant model in the field and we propose that PML/RARA initiates leukemia by subtly shifting cell fate decisions within the promyelocyte compartment. PMID: 26088929
29. RARalpha might be involved in the pathogenesis of varicocele as its expression is reduced in pathologic samples. PMID: 24992177
30. The PML-region mutations were associated with response to Arsenic trioxide-based therapy (P < 0.0001), number of relapses (P = 0.001), and early relapse (P = 0.013)in acute promyelocytic leukemia patients. PMID: 26294332
31. Data show that the tumor suppressor RASSF1A is a direct target of the PML/RARalpha-regulated microRNAs miR-181a/b cluster. PMID: 26041820
32. These results suggest that overexpression of RARA enhances malignant transformation during mammary tumorigenesis. PMID: 25300573
33. E2F1 is found to downregulate retinoic acid receptor alpha (RARalpha), a key factor determines the effectiveness of all-trans retinoic acid. PMID: 24608861
34. bortezomib impairs the UPS that controls normal protein homeostasis by causing excessive accumulation of PML-RARA augmenting ER stress and leading to acute promyelocytic leukemia cell death PMID: 26026090
35. CDKN2D repression by PML/RARalpha disrupts both cell proliferation and differentiation in the pathogenesis of acute promyelocytic leukemia. PMID: 25275592
36. These results indicate that NPM-RAR, not RAR-NPM, is the prime mediator of myeloid differentiation arrest in t(5;17) APL. PMID: 23927396
37. This study identifies a novel mechanism through which NPM-RAR affects leukemogenesis PMID: 25033841
38. Data indicate that retinoic acid receptor (RAR) is crucial for regulating sodium taurocholate cotransporting polypeptide (NTCP) expression that determines permissiveness to hepatitis B virus (HBV) infection. PMID: 25550158
39. Human miR-138 promotes tau phosphorylation by directly targeting the RARA and the associated GSK-3beta pathway. PMID: 25680531
40. Down-regulation of NLS-RARalpha expression inhibited the proliferation and induced the differentiation of HL-60 cells. On the contrary, over-expression of NLS-RARa promoted proliferation and reduced the ATRA-induced differentiation of HL-60 cells. PMID: 24516348
41. PML-RARalpha cooperates with HIF-1alpha to activate a pro-leukemogenic program. PMID: 24711541
42. Results show that UTX interacts with the retinoic acid receptor alpha (RARalpha) and this interaction is essential for proper differentiation of leukemic U937 cells in response to retinoic acid. PMID: 25071154
43. SUMO-1 modification of RARA is a potent mechanism for balancing proliferation and differentiation by controlling the stability of RARA in cancer cells. PMID: 24819975
44. The current status of knowledge indicates that there might be inter- or overlapping actions between PPARg and RARs, and there might be an association of PPARg/RARs(RARa, RARb, and RARg) with renal diseases PMID: 24050824
45. PML/RARalpha suppresses PU.1-dependent activation of the proteasome immunosubunits in acute promyelocytic leukemia. PMID: 23770850
46. The presence of a mutation in the arsenic-binding domain of PML-RARA led to arsenic resistance in patients with acute promyelocytic leukemia. PMID: 24806185
47. The objective was to describe the frequency of molecular subtypes of PML/RARalpha in patients with acute promyelocytic leukemia (APL) and their distribution according to risk of recurrence and cytomorphology PMID: 23612809
48. provide evidence for the existence of a functional ternary complex containing TDG, CBP and activated RARalpha PMID: 24394593
49. Differences in RAR and RXR subtype mRNA expression patterns in various PTCs may contribute to the immunochemistry data available, and may thus find exploitation in clinical oncology, particularly in the differential diagnosis of thyroid neoplasms. PMID: 23969901
50. The tumor suppressor gene DAPK2 is induced by the myeloid transcription factors PU.1 and C/EBPalpha during granulocytic differentiation but repressed by PML-RARalpha in APL. PMID: 24038216
顯示更多

收起更多
相關(guān)疾病：

Chromosomal aberrations involving RARA are commonly found in acute promyelocytic leukemia. Translocation t(11;17)(q32;q21) with ZBTB16/PLZF; translocation t(15;17)(q21;q21) with PML; translocation t(5;17)(q32;q11) with NPM. The PML-RARA oncoprotein requires both the PML ring structure and coiled-coil domain for both interaction with UBE2I, nuclear microspeckle location and sumoylation. In addition, the coiled-coil domain functions in blocking RA-mediated transactivation and cell differentiation.
亞細胞定位：

Nucleus. Cytoplasm.
蛋白家族：

Nuclear hormone receptor family, NR1 subfamily
組織特異性：

Expressed in monocytes.
數(shù)據(jù)庫鏈接：

HGNC: 9864

OMIM: 180240

KEGG: hsa:5914

STRING: 9606.ENSP00000254066

UniGene: Hs.654583

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human